WCLC 2025 - Posters & ePosters-EP.09.08 Outcomes of SBRT in the Management of Adrenal Metastases From Lung Cancer - Retrospective Data From Tertiary Cancer Centre of India

EP.09.08 Outcomes of SBRT in the Management of Adrenal Metastases From Lung Cancer - Retrospective Data From Tertiary Cancer Centre of India

Back to course

Pdf Summary

This retrospective study from Tata Memorial Hospital, India, evaluates the outcomes of stereotactic body radiation therapy (SBRT) in managing adrenal gland metastases (AGM) originating from lung cancer. Lung cancer is a common cause of AGM, seen in up to 20% of patients. SBRT, a non-invasive therapy, offers a promising treatment option, particularly for patients with oligometastatic disease.<br /><br />The analysis included 20 lung cancer patients with adrenal metastases treated with SBRT between January 2017 and December 2024. Most patients were male (80%) with a median age of 62.5 years; the majority had adenocarcinoma histology (65%). Presentations included synchronous (70%) and metachronous (30%) metastases. Treatment primarily targeted oligometastasis, oligoprogression, or oligorecurrence, with 70% receiving SBRT with radical intent. Median tumor volume (GTV) was 12 cc, treated with a median dose of 38 Gy over 5 fractions.<br /><br />Results demonstrated excellent local control (LC) rates of 90% at 1 year and 75% at 2 years post-SBRT. Progression-free survival (PFS) was 50% at 1 year but dropped to 12% at 2 years, while overall survival (OS) was 61% at 1 year and 21% at 2 years. Median OS was significantly longer in metachronous AGM (25.7 months) versus synchronous AGM (6.8 months). Univariate analysis showed better OS with metachronous presentation and improved PFS in patients with smaller tumor volume (≤12 cc); however, multivariate analysis did not confirm statistical significance. Toxicity was minimal, with 10% experiencing grade 1-2 fatigue or diarrhea; no grade 3+ toxicities or renal injuries were reported.<br /><br />In conclusion, SBRT provides effective local control with minimal toxicity for adrenal metastases from lung cancer, especially in patients with small tumors and metachronous presentations. The study advocates for larger prospective trials with rigorous patient selection to better refine prognostic factors and optimize treatment outcomes in this setting.

Asset Subtitle

Memtombi Ngasepam

Meta Tag

Speaker Memtombi Ngasepam

Topic Metastatic Non-small Cell Lung Cancer – Local Therapies

Keywords

Stereotactic Body Radiation Therapy

SBRT

Adrenal Gland Metastases

AGM

Lung Cancer

Oligometastatic Disease

Local Control

Progression-Free Survival

Overall Survival

Tata Memorial Hospital